We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

93 hedge funds and large institutions have $60.4M invested in Summit Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,170% more call options, than puts

Call options by funds: $2.1M | Put options by funds: $165K

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

0.38% less ownership

Funds ownership: 5.01% → 4.63% (-0.38%)

7% less funds holding

Funds holding: 100 → 93 (-7)

31% less capital invested

Capital invested by funds: $87.7M → $60.4M (-$27.3M)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

Holders
93
Holders Change
-7
Holders Change %
-7%
% of All Funds
1.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
34
Reduced
22
Closed
15
Calls
$2.1M
Puts
$165K
Net Calls
+$1.93M
Net Calls Change
+$1.99M

Top Buyers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
+$1.2M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$530K
3
BlackRock
BlackRock
New York
+$408K
4
Barclays
Barclays
United Kingdom
+$190K
5
JP Morgan Chase
JP Morgan Chase
New York
+$186K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$6.03M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$482K
3
Group One Trading
Group One Trading
Illinois
-$350K
4
Goldman Sachs
Goldman Sachs
New York
-$303K
5
Millennium Management
Millennium Management
New York
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Board of Administration of Florida Retirement System
51
State Board of Administration of Florida Retirement System
Florida
$61.8K +$324 +170 +0.5%
RG
52
Rathbones Group
United Kingdom
$56.7K +$57.8K +30,317 New
AGM
53
Alpine Global Management
New York
$56.1K – – –
BFM
54
Boothbay Fund Management
New York
$56.1K – – –
CG
55
Cutler Group
California
$54K -$1.11K -584 -2%
Wells Fargo
56
Wells Fargo
California
$52.8K -$47.7K -25,021 -47%
T. Rowe Price Associates
57
T. Rowe Price Associates
Maryland
$51K +$6.55K +3,435 +15%
Zurich Cantonal Bank
58
Zurich Cantonal Bank
Switzerland
$47.9K -$1.25K -653 -2%
BRA
59
Bender Robert & Associates
California
$45K – – –
SAM
60
Sectoral Asset Management
Quebec, Canada
$37.4K -$57.2K -30,000 -60%
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$36K +$14K +7,331 +60%
AQR Capital Management
62
AQR Capital Management
Connecticut
$36K +$36.7K +19,225 New
CUAMC
63
China Universal Asset Management Company
China
$33.5K +$16.7K +8,758 +96%
Federated Hermes
64
Federated Hermes
Pennsylvania
$33.4K +$34.1K +17,877 New
AB
65
Amalgamated Bank
New York
$33K – – –
Mirae Asset Global Investments
66
Mirae Asset Global Investments
South Korea
$30.7K +$1.18K +617 +4%
TSW
67
Three Seasons Wealth
Utah
$24.1K +$24.5K +12,869 New
BF
68
Blankinship & Foster
California
$23.9K – – –
Victory Capital Management
69
Victory Capital Management
Texas
$22.9K +$694 +364 +3%
Principal Financial Group
70
Principal Financial Group
Iowa
$22.6K -$3.04K -1,595 -12%
IC
71
Inscription Capital
Texas
$22.4K – – –
WAM
72
Worth Asset Management
Texas
$20.5K – – –
SEI Investments
73
SEI Investments
Pennsylvania
$19.4K – – –
SIG
74
Sargent Investment Group
Maryland
$18.7K – – –
AIP
75
Ameritas Investment Partners
Nebraska
$17.9K – – –
1 2
3
4 5

SMMT Hedge Fund Activity: Q3 2023 in Review

93 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2023, worth a combined $60.4M — down 31% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of SMMT and 8 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 34 added.

The largest buyer was Charles Schwab, adding an estimated $1.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.03M.

  • 93 institutional investors held Summit Therapeutics (SMMT) as of Q3 2023, down from 100 in Q2 2023.
  • Funds reported $60.4M of Summit Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
  • 8 funds opened new Summit Therapeutics positions in Q3 2023 and 15 closed out, a net change of -7 holders.
  • The largest Summit Therapeutics buyer in Q3 2023 was Charles Schwab, an estimated $1.2M added.
  • The largest Summit Therapeutics seller in Q3 2023 was Baker Bros. Advisors, an estimated $6.03M sold.

Based on aggregated 13F filings for Q3 2023.